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Summary
Objective: To determine the in-vitro effects of several non-steroidal antiinflammatory drugs and the glucocorticoid dexamethasone on the IL-1
altered expression and activity of MMP-1, MMP-3 and TIMP-1 by bovine articular chondrocytes.
Design: Bovine chondrocytes were cultured in alginate gel beads. Cells were treated with IL-1 in the presence of vehicle or drugs at various
concentrations. After 48 h mRNA expression of MMP-1, MMP-3, and of the tissue inhibitor of metalloproteinases (TIMP-1) was analysed by
RT-PCR-ELISA. The protein synthesis of TIMP-1 and MMP-3 was determined by immunoprecipitation. The activity of enzymes and inhibitors
was measured by functional assays.
Results: IL-1 increased the expression and activity of MMPs. In contrast, TIMP activity remained unchanged although TIMP-1 expression
was down-regulated. All tested NSAIDs and dexamethasone inhibited collagenase activity induced by IL-1. Transcript levels of MMP-1,
however, were only reduced by indomethacin, meloxicam, naproxen and dexamethasone. Proteoglycanase activity was only reduced by
indomethacin, meloxicam and dexamethasone. These effects were pre-translational as confirmed by immunoprecipitation. The IL-1
decreased expression of TIMP-1 was further reduced by dexamethasone, which resulted in a significant loss of TIMP activity. No effects on
TIMP activity or TIMP-1 biosynthesis were observed after treatment of chondrocytes with NSAIDs.
Conclusion: Our studies clearly demonstrate that marked differences exist between individual NSAIDs with respect to their ability to modulate
the imbalance between proteases and inhibitors during OA and RA, suggesting that the respective modes of action are independent of the
inhibition of cyclooxygenases. Due to their co-regulation of MMPs and TIMP(s) glucocorticoids should be carefully studied for their overall
effect on ECM proteolysis. © 2001 OsteoArthritis Research Society International
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A common feature of joint diseases like osteoarthritis (OA)
and rheumatoid arthritis (RA) is the destruction of articular
cartilage. Integrity of a functional matrix, which in the
healthy joint serves to distribute loads over bone surfaces
and provides a low-friction surface over which bones can
move, is impaired by dysregulated production of matrix
components and proteolytic enzymes. The matrix metallo-
proteinases (MMPs) in concert with the recently identified
aggrecanases (ADAMTS4 and -11), which are members of
the ADAMTS (a disintegrin and metalloproteinase with
thrombospondin motifs) family1,2 are collectively capable
of degrading essentially all cartilage extracellular matrix407components (ECM). The MMPs, zinc-dependent endo-
peptidases, comprise an enzyme superfamily of at least 21
members, which can be classified into subgroups of colla-
genases, stromelysins, gelatinases and membrane-type
MMPs. The collagenases (MMP-1, -8, -13) are distin-
guished from other MMPs by their unique ability to cleave
triple helical regions of the major cartilage collagen, i.e.
collagen type II. Identification of MMP-specific collagen
cleavage products in human RA and OA cartilage has
established a significant correlation between collagenase
activities and tissue destruction during these diseases3.
Stromelysin-1 (MMP-3), on the other hand, is involved in
the degradation of aggrecan by cleavage at the Asn341-
Phe342 site resulting in the neoepitope sequence VDIPEN4.
Although it has been argued that cleavage at the Glu373-
Ala374 site by aggrecanases is mainly responsible for
aggrecan degradation5, VDIPEN neoepitopes were found
in synovial fluid as well as in cartilage of RA and OA
patients6. Additionally, when experimental RA was induced
in MMP-3-deficient mice articular cartilage remained intact
whereas in wild-type mice severe erosion was observed7.
Apart from a pivotal role in cartilage degradation MMP-3 is
essential for full activation of proMMP-18.
MMP activity is controlled by tissue inhibitors of metallo-
proteinases (TIMPs) which form inhibitory complexes with
408 T. Sadowski and J. Steinmeyer: Effects of non-steroidal antiinflammatory drugsMMPs in a 1:1 stochiometry. To date four different TIMPs
(TIMP-1, -2, -3, -4) are known9, however, their specific
roles are not well understood. TIMP-1 to -3 were found to
be expressed by chondrocytes10,11, and therefore are
possibly essential for maintaining an enzyme-inhibitor bal-
ance required for physiological ECM turnover. Pathologic
proteolysis of cartilage components during OA and RA on
the other hand is believed to be the result of an excess of
MMPs in comparison to TIMPs12.
Cytokines from synovial membrane like interleukin-1
(IL-1) can markedly alter the metabolic activity of chondro-
cytes. Elevated levels of IL-1 have been found in synovial
fluid from patients suffering OA or RA13. IL-1 has been
found to contribute to the disease process by stimulating
the biosynthesis of proteolytic enzymes14, and also by
inhibiting the production of extracellular matrix constituents
such as collagen and PGs from articular cartilage15,16. The
resulting imbalance between the anabolic and catabolic
activities leads to the severe degradation of articular
cartilage observed in OA.
Non-steroidal antiinflammatory drugs (NSAIDs) and
glucocorticoids belong to the most frequently used drugs in
OA and RA therapy. Despite their therapeutic efficacy in
modulating pain and inflammation, their influence on carti-
lage metabolism is still under discussion. For instance,
some NSAIDs have been shown to influence the PG and
collagen synthesis rates in articular cartilage17–19; how-
ever, few studies focused on the extent to which various
NSAIDs can modulate the proteolytic activities in chondro-
cytes20,21. Suppression of MMP synthesis by glucocorti-
coids has been reported22,23, but little is known about the
effects of steroids on TIMPs. Here, we report that, first,
the NSAIDs acetylsalicylic acid (ASA), diclofenac-Na,
indomethacin, meloxicam and naproxen profoundly differ in
their ability to modulate proteolytic activities by articular
chondrocytes; second, MMP-1 and MMP-3 differ in their
responses to NSAIDs, and finally, dexamethasone simul-
taneously suppresses production of TIMP-1 and MMPs by
articular chondrocytes.Materials and methods
MATERIALS
Pronase®, protein G PLUS/protein A agarose and anti-
TIMP-1 antibody were purchased from Calbiochem (Bad
Soden, Germany), ascorbate, penicillin, streptomycin,
L-glutamine, alpha-ketoglutarate, 6-aminocaproic acid,
N-ethylmaleimide, 4-aminophenylmercuric acetate
(APMA), phenylmethylsulfonyl fluoride (PMSF), ortho-
phenylenediamine (OPD), bovine type I collagen, antigoat
IgG peroxidase conjugate, mouse IgG, and rabbit IgG
were obtained from Sigma (Deisenhofen, Germany).
Streptavidin-peroxidase conjugate, 72 kDa gelatinase, low
range protein molecular weight marker, DIG labeling mix,
biotin labeling mix and PCR ELISA were from Boehringer
(Mannheim, Germany), alginate from Kelco (London, U.K.),
and collagenase CLS-2 as well as trypsin were purchased
from Worthington (Freehold, U.S.A.). Ham’s F12, fetal
bovine serum (FBS), gentamycin, and Trizol® were
obtained from Life Technologies (Eggenstein, Germany),
human recombinant IL-1 from R&D Systems (Wiesbaden,
Germany), and soybean trypsin inhibitor from Fluka
Chemie (Deisenhofen, Germany). Goat antitype I collagen
antibody was ordered from Southern Biotechnology Associ-
ation (Birmingham, U.K.), and M-MLV reverse transcriptaseas well as Taq polymerase from Promega (Mannheim,
Germany). CR-ITS+Y was purchased from Collaborative
Research (Bedford, U.K.), anti-MMP-3 antibody from
Chemicon International (Hofheim, Germany), gelatine from
Bio-Rad (Richmond, U.S.A.) and Easy TaqY express pro-
tein labeling mix [35S] from NEN (Dreieich, Germany).
Drugs were generous gifts from the following pharmaceu-
tical companies listed in parentheses: ASA (Bayer AG),
diclofenac-Na (Ciba Geigy AG), indomethacin (Merck KG),
meloxicam (Boehringer Ingelheim), naproxen (SmithKline
Beecham GmbH), dexamethasone (Merck KG).CULTURE OF CHONDROCYTES
Chondrocytes were isolated from macroscopically
healthy metacarpophalangeal joints of 18–24-month-old
steers and subsequently encapsulated in alginate beads.
Cells were released from the matrix by initial digestion with
pronase (0.8% w/v) for 1 h at 37°C followed by collagenase
(0.5% w/v) digestion for 4 h at 37°C. Viability of the har-
vested cells, as assessed by the trypan blue exclusion test,
was always greater than 95%. Chondrocytes were sus-
pended in sterile alginate solution (1.2% w/v) to a final
concentration of 3×106 cells/ml alginate. The preparation
of alginate beads was done as described earlier24. Twenty
beads (approx. 6×105 cells) per well were transferred to a
12-well culture dish containing 2.5 ml per well growth
medium (Ham’s F12 containing 10% (v/v) FBS, 25 mM
HEPES, 0.3 mg/ml L-glutamine, 0.03 mg/ml alpha-
ketoglutarate, 0.05 mg/ml ascorbic acid, 10 U/ml penicillin
and 0.1 mg/ml streptomycine). Media were changed every
second day. Cultures were maintained for 8 days at 37°C,
5% CO2 and 95% humidity. At day 4 serum was reduced to
5% (v/v) and 0.5% (v/v) of the serum substitute CR-ITS+Y
was added to the media. During the final 48 h, culture
medium containing 1% (v/v) CR-ITS+Y instead of FBS25,
and IL-1 at a final concentration of 0.5 ng/ml were given to
the cells either alone or together with NSAIDs (1 M to
50 M) or dexamethasone (0.1 M to 50 M) or the drug
vehicle, respectively. After the incubation period media
were collected and stored frozen at −20°C. Cells were
harvested by solubilization of the alginate beads in citrate
buffer (55 mM sodium citrate and 150 mM NaCl, pH 7.2,
1 ml per 20 beads) with subsequent centrifugation. The
alginate supernatant and the chondrocytes were stored
frozen at −20°C until analysed.DETERMINATION OF TIMP ACTIVITY
The activity of TIMP(s) was quantitated by its ability to
inhibit the 72kDa gelatinase (MMP-2) in a solid-phase
assay employing biotin labeled gelatin adsorbed onto
microtiter plate wells as substrate26. Briefly, gelatin was
biotinylated by the use of a biotin labeling kit (Boehringer)
according to the manufacturer’s instructions. Biotin-labeled
gelatin was diluted in carbonate buffer (15 mM Na2CO3 and
35 mM NaHCO3, pH 9.6) to a final concentration of 25 ng/
ml. The wells of a 96-well microtiter plate were coated with
50 l of this solution and unbound gelatin was removed by
repeated washing with PBS (1.5 mM KH2PO4, 8.1 mM
Na2HPO4, 137 mM NaCl and 2.7 KCl, pH 7.2). Wells were
then blocked with unlabeled gelatin, and the plates were
stored at 4°C until used. MMP-2 was activated by addition
of 1 mM APMA and then diluted in Tris buffer (50 mM Tris,
5 mM CaCl and 0.05% Triton X-100, pH 7.5) to a final2
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with or without conditioned media and solubilized alginate
samples. This mixture was subsequently added in dupli-
cate to the wells of the prepared microtiter plate. After
75 min incubation at 37°C, the enzyme reaction was
stopped by repeated washing with PBS-Tween (PBS with
0.05% Tween 20). The remaining amount of undigested
gelatin was measured with a streptavidin–peroxidase con-
jugate. Conversion of the peroxidase substrate OPD was
measured in an ELISA photometer at 492 nm. One unit of
inhibitor activity was defined as 1% inhibition of gelatinolytic
activity. A standard curve of MMP-2 was included in each
experiment to reduce variability due to coating differences
between individual microtiter plates.DETERMINATION OF MMP ACTIVITY
Media samples were assayed for collagenolytic activity
by their ability to degrade collagen type I coated on
microtiter plate wells as previously described27. Briefly,
proenzymes were activated by treatment with trypsin
(0.1 mg/ml) for 20 min at 37°C. Soybean trypsin inhibitor
was subsequently added to stop the reaction (0.5 mg/ml for
10 min at 37°C). The samples were then added in duplicate
to the wells of microtiter plates coated with bovine type I
collagen. After 2 h of incubation at 37°C the reaction was
stopped by addition of EDTA (25 mM). The remaining
amount of undigested collagen was detected with a goat
antitype I collagen antibody, followed by the addition of a
peroxidase-conjugated antigoat IgG antibody. Conversion
of OPD was measured in an ELISA photometer at 492 nm.
One unit of MMP collagenolytic activity was defined as the
digestion of 1% collagen as compared with the undigested
control. A linear relationship between the amount
of enzyme and substrate digestion was confirmed in
preliminary experiments (data not shown).
The MMP proteoglycanolytic activity was determined as
previously described28. Briefly, MMPs in the media were
activated by addition of 1 mM APMA for 6 h at 37°C. The
samples were then diluted in a reaction mixture containing
60 mM Tris, 5 mM CaCl2, 80 mM NaCl and 0.02% Brij-35®,
pH 7.5 and proteinase inhibitors (100 mM 6-aminocaproic
acid, 2 mM PMSF, 10 mM N-ethylmaleinimide). The mix-
ture was added to a glass scintillation vial containing ∼2 mg
[3H]proteoglycan (PG) monomers entrapped in polyacryla-
mid gel beads. PG monomers were purified from bovine
nasal septum cartilage and labeled with [3H]acetic anhy-
dride. The radiolabeled PG monomers were entrapped in
polyacrylamide gel beads with a pore size that retains the
monomers but permits the escape of digestion products
smaller than ∼200 000 Da29. After incubation for 16 h at
37°C in a rocking water bath, 6 ml scintillation cocktail was
added and the radioactivity was determined by using a
liquid scintillation counter. One unit of MMP proteoglycano-
lytic activity was defined as one count per minute of tritium
released per mg PG beads. A linear relationship between
the amount of enzyme and substrate digestion was con-
firmed in preliminary experiments (data not shown). Control
experiments, performed in the presence of EDTA or 1,10-
phenanthroline, revealed that both assays measured only
MMP-dependent proteolytic activities. No activity could be
detected in solubilized alginate fractions, possibly because
of the Ca2+-binding properties of the citrate buffer used for
dissolving the alginate beads.RNA ISOLATION AND REVERSE TRANSCRIPTION–POLYMERASE
CHAIN REACTION (RT–PCR)
Total RNA was isolated from chondrocytes using Trizol®
according to the manufacturer’s instructions. For the gen-
eration of single stranded cDNA, 0.25 g RNA was incu-
bated with 50 pmol oligo dT primer and 200 units M-MLV
reverse transcriptase for 90 min at 42°C with a final de-
naturation step at 95°C for 15 min. The cDNA was diluted
in sterile water and then stored at −20°C. The following
primer pairs were chosen from the published sequences
and used for amplification30–34.
TIMP-1: 5′-ATGGCCTCTGGCATCCTGTTG-3′, 5′-AAAG
GTGGGAGTGGAAACACG-3′, MMP-1: 5′-AACTCTGGA
GCAATGTCACAC-3′, 5′-CCTCATAATCAGCTTGAAGTC-
3′, MMP-3: 5′-GAAATGCA GAAGTTCCTTGG-3′, 5′-GTG
AAAGAGACCCAGGGAGTG-3′, GAPDH: 5′-GAGATGAT
GACCCTTTTGG-3′, 5′-GTGAAGGTCGGAGTCAACG-3′.
Depending on the cDNA to be amplified, PCR was per-
formed for 22–28 cycles (denaturing at 95°C for 45 sec,
annealing for 60 sec, extension at 72°C for 120 sec) to
keep the reaction in the exponential range of amplification
and thus obtain semiquantitative results (data not shown).
PCR products were labeled with digoxigenin (DIG) by
addition of a DIG labeling mix to the reaction mixture. This
mixture further contained 50 mM KCl, 10 mM Tris, 0.1%
Triton® X-100, 1.5 mM MgCl2, 20 pmol primer, 1 unit Taq
polymerase and 2.5 l cDNA, respectively, negative control
in a total volume of 25 l. PCR products were commercially
sequenced (MWG Biotech, Ebersberg, Germany), which
revealed their identity to the predicted sequences (28–35).PCR-ELISA
DIG-labeled PCR products were quantitated by the use
of a PCR ELISA kit according to the manufacturer’s instruc-
tions. Briefly, DIG-labeled PCR products were immobilized
to streptavidin-coated microtiter plate wells by hybridization
to a biotinylated oligonucleotide that was complementary to
a ∼20 bp spanning sequence in the inner part of the
DIG-labeled PCR product. The bound hybrids were
detected by an antidigoxigenin peroxidase conjugate and
by the use of the colorimetric substrate ABTS®. Absorb-
ance was read in an ELISA photometer at 405 nm and was
taken as a measure for the amount of amplified product.
Expression of GAPDH was taken as internal control.TIMP-1 AND MMP-3 IMMUNOPRECIPITATION
TIMP-1 and MMP-3 protein synthesis was analysed by
metabolic labeling of chondrocytes followed by immuno-
precipitation. Cells were radiolabeled with 50 Ci/ml
[35S]methionine/cysteine during the final 18 h of the incu-
bation period with IL-1 and drugs. Media and alginate
samples were pooled and pre-cleared by incubation with
non-immunne mouse IgG (TIMP-1) or non-immune rabbit
IgG (MMP-3) and protein G plus /protein A agarose sus-
pension for 1 h. Mouse anti-TIMP-1 antibody (0.5 g/ml),
which detected free TIMP-1 as well as TIMP-1 complexed
with MMPs, or rabbit anti-MMP-3 antibody (2 g/ml), which
detected the active and latent form of the enzyme, was
added to the samples. After overnight incubation at 4°C,
immune complexes were precipitated by the addition of a
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were washed three times in Tris buffer (10 mM Tris,
150 mM NaCl, 1 mM EDTA and 1% Triton X-100, pH 7.4),
boiled for 5 min in Laemmli buffer and were then separated
on 10% SDS-polyacrylamide gels under reducing con-
ditions. Gels were stained with Coomassie Brilliant Blue R
250 for visualization of molecular weight marker proteins,
fixed and dried. The radioactivity of the single protein bands
at 27kDa (TIMP-1) and 58kDa (proMMP-3) was measured
with the Automatic TLC-Linear Analyser LB284/LB285
(Berthold, Wildbad, Germany). Peaks were analysed with
the Chroma 1D software (Berthold).
For the determination of the synthesis of total protein,
cells were first released from alginate beads by solubiliz-
ation in citrate buffer and then resuspended in lysis buffer
(10 mM Tris, 150 mM NaCl, 1 mM EDTA, 1% (v/v) Triton®
X-100, 2 mM PMSF, pH 7.4). After centrifugation, proteins
in the supernatant were precipitated by the addition of 0.5
M perchloroacetic acid (PCA). Precipitates were applied
to Whatman GF/C-filters and extensively washed with 0.25
M PCA. Filters were dried and the filter-associated
radioactivity was quantitated by liquid scintillation counting.STATISTICAL ANALYSIS
Data were collected from four to six independent experi-
ments. Samples were determined in duplicate and groups
of data were analysed using Student’s one-tailed paired
t-test. Significance was set P≤0.05. Data are presented as
mean±standard deviation (S.D.).ResultsEFFECTS OF IL-1 ON THE PRODUCTION OF PROTEASES AND
INHIBITORS
Initially, we stimulated chondrocytes with various con-
centrations of IL-1 (data not shown). The concentration ofthe cytokine (0.5 ng/ml) that was used in our study caused
submaximal effects on the expression and activity of
enzymes and inhibitors (Table I). Unstimulated chondro-
cytes produced detectable but low levels of enzymes.
Incubation with IL-1 for 48 h led to a substantiated rise of
metalloproteolytic activities with a concomittant increase of
MMP-1 and MMP-3 expression. No effects were observed
on TIMP activities in the culture supernatants, although
mRNA expression and protein synthesis of TIMP-1 was
significantly reduced by cytokine action. These data indi-
cate that treating chondrocytes with IL-1 induced an excess
of MMPs in comparison with TIMP(s).Table I
Activity and expression of MMPs and TIMP(s) after treatment of
chondrocytes with 0.5 ng/ml IL-1 for 48 h
Control IL-1
Activity (U/106 cells)
Collagenase 86.2±102.4 1054.9±675.9c
Proteoglycanase 392.7±526.1 2935.6±1261.2c
TIMP 933.7±473.4 928.3±412.0
mRNA expression (arbitrary units)
MMP-1 1.2±2.2 6.9±5.4b
MMP-3 1.7±1.5 8.1±5.5b
TIMP-1 14.7±10.5 9.1±6.7a
Protein synthesis (cpm/106 cells)
MMP-3 1.1±3.8 51.3±25.8c
TIMP-1 131.5±35.4 65.1±26.8c
Experiments were performed between culture days 6 and 8 in
the presence of the serum substitute CR-ITS+Y. MMP activity was
assayed in conditioned media, whereas the activity of TIMP was
determined in conditioned media as well as in solubilized alginate
samples. The definition of units is described under Materials and
methods. mRNA expression was determined by quantitating PCR
products with a PCR-ELISA. Protein expression was quantitated
by immunoprecipitation. Values are mean±S.D. (N=6). Groups
of data were analysed using Student’s one-tailed paired t-test.
Statistical significance different from untreated control values:
a0.01<P≤0.05, b0.001<P≤0.01, cP≤0.001.DRUG EFFECTS ON COLLAGENASE ACTIVITY AND mRNA
EXPRESSION OF MMP-1
In a first set of experiments we incubated chondrocytes
with IL-1 and drugs at a concentration of 10 M and, after
48 h, determined collagenase activity and transcript levels
of MMP-1. This primary screen revealed that all tested
NSAIDs and dexamethasone significantly reduced enzyme
activity and/or mRNA expression of MMP-1 [Table II(a)].
Drugs were then tested at additional concentrations to
obtain pharmacokinetic data. In these studies a clear
concentration-dependent reduction of collagenase activity
and transcript levels of MMP-1 was observed for indometh-
acin, meloxicam and naproxen. A 50% inhibition of enzyme
activity (IC50) and MMP-1 transcript level was achieved
by meloxicam at calculated IC50 values of 7.3 M and
25.1 M, respectively. However, we did not reach a 50%
inhibition even at an exceedingly high concentration of
50 M of indomethacin and naproxen. On the other hand,
after treating chondrocytes with ASA and diclofenac-Na,
enzyme activities were lowered by 40% and 60%, respect-
ively, at all concentrations tested. Surprisingly, these drugs
did not alter the steady-state level of MMP-1 mRNA,
indicating that their inhibitory action might be exerted
post-transcriptionally. Finally, the IL-1 increased colla-
genase activity and MMP-1 expression was completely
reversed by dexamethasone at all concentrations tested
[Table II(b)].Table II(a)
Effects of NSAIDs and dexamethasone on collagenase activity and
mRNA expression of MMP-1
Condition Collagenase
activity
MMP-1 mRNA
expression
IL-1 100 100
+ASA 65.93±17.2b 101.02±35.9
+diclofenac-Na 56.37±16.5c 80.74±38.3
+indomethacin 68.22±16.9b 42.19±33.1a
+meloxicam 40.15±8.0c 62.06±20.9b
+naproxen 90.01±25.4 59.40±27.9c
+dexamethasone 6.96±17.0c 21.84±29.6b
Experiments were performed between culture days 6 and 8 in
the presence of the serum substitute CR-ITS+Y. Drugs were given
to chondrocytes to a final concentration of 10 M. MMPs in media
samples were activated with trypsin and analysed for enzymatic
activities against collagen type I. MMP-1 mRNA expression was
determined by RT-PCR-ELISA. Values are expressed in
mean±S.D. (N=4–6). Data were analysed using Student’s one-
tailed paired t-test. Statistical significance different from control
values (IL-1+vehicle=100%): a0.01<P≤0.05, b0.001<P≤0.01,
cP≤0.001.
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Again, drugs were initially given to chondrocytes at a
concentration of 10 M. In contrast to the results obtained
on the inhibition of collagenase activity only meloxicam and
dexamethasone could reduce the IL-1 stimulated proteo-
glycanase activity [Table III(a)]. However, indomethacinsignificantly lowered the transcript level and protein syn-
thesis of MMP-3 and was therefore tested at additional
concentrations. These experiments revealed that at con-
centrations below 10 M indomethacin failed to reduce the
expression of MMP-3 whereas with the maximum concen-
tration tested (50 M) an inhibition of enzyme activity by
∼45% could be achieved. Similar results were obtained for
meloxicam, although we still observed significantly reduced
proteoglycanase activity at a drug concentration of 5 M. In
comparison, dexamethasone completely abolished the IL-1
induction of enzyme activity and expression of MMP-3 even
at the lowest concentration tested [Table III(b)].DRUG EFFECTS ON TIMP ACTIVITY AND THE BIOSYNTHESIS OF
TIMP-1
TIMP(s) plays a pivotal role in the control of metallopro-
teolytic activites. An increase or decrease of the production
of inhibitor(s) would ultimately lead to an altered net pro-
teolysis of cartilage components. Therefore, we examined
the influence of NSAIDs and dexamethasone on TIMP
activity and the biosynthesis of TIMP-1. Drugs were initially
tested at 10 M in the presence of IL-1. Whereas none of
the tested NSAIDs reversed the IL-1 decreased expression
of TIMP-1, Table IV demonstrates that TIMP activity and
expression of TIMP-1 were further lowered in the presence
of dexamethasone. Further experiments with additional
concentrations revealed that inhibition was concentration-
independent. Protein and mRNA expression of TIMP-1
was always diminished by ∼60% and ∼40%, respectively.
Meloxicam reduced TIMP activity at concentrations of
10 M and higher, although this drug did not alter the
production of TIMP-1 (Table IV).DRUG EFFECTS ON THE VIABILITY AND PROTEIN SYNTHESIS OF
IL-1 TREATED ARTICULAR CHONDROCYTES
The viability of chondrocytes after treatment with IL-1 in
the absence or presence of NSAIDs and dexamethasone
was assessed by the trypan blue exclusion test. Neither the
cytokine nor the drugs significantly altered the untreated
control values which were always above 90% viable cells,
indicating that these drugs have no cytotoxic effects on
chondrocytes. Furthermore, the addition of NSAIDs to IL-1
treated chondrocytes did not alter the synthesis of totalTable II(b)
Collagenolytic activity and mRNA expression of MMP-1 after
treatment of chondrocytes with 0.5 ng/ml IL-1 and various concen-
trations of NSAIDs and dexamethasone for 48 h
Collagenolytic
activity
mRNA
expression
ASA
50 M 53.91±10.4c 115.86±28.9
5 M 59.15±18.8b 103.28±35.2
1 M 58.89±17.6a 107.94±34.7
Dexamethasone
50 M 15.98±13.3c 7.37±3.9c
1 M 9.30±8.4c 6.48±4.1c
0.1 M 3.67±8.2c 6.38±1.9c
Diclofenac-Na
50 M 37.75±34.8c 93.81±24.4
5 M 33.15±15.2c 118.39±35.4
1 M 36.54±21.1c 105.81±26.4
Indomethacin
50 M 60.76±15.2b 55.14±24.5b
5 M 79.84±26.7a 90.10±27.7
1 M 80.89±33.1 88.20±23.4
Naproxen
50 M 51.35±15.1c 76.79±17.7a
5 M 66.54±21.9b 99.22±32.2
1 M 89.27±21.5 94.94±27.2
Meloxicam
50 M 31.63±19.9c 45.23±18.4c
5 M 63.75±20.1b 105.31±35.2
1 M 108.77±26.2 108.17±23.4
Experiments were performed between culture days 6 and 8 in
the presence of the serum substitute CR-ITS+Y. Enzyme activities
were determined in media samples. Total RNA was isolated and
analysed by RT-PCR-ELISA. All analyses were performed as
described under Materials and methods. Values are mean±S.D.
(N=4–6). Statistical significance different from control values (IL-
1+vehicle=100%): a0.01<P≤0.05, b0.001<P≤0.01, cP≤0.001.Table III(a)
Effects of NSAIDs and dexamethasone on proteoglycanase activity and biosynthesis of MMP-3
Condition Enzyme
activity
MMP-3
protein synthesis
MMP-3
mRNA expression
IL-1 100 100 100
+ASA 115.75±53.6 93.78±8.6 98.33±39.1
+diclofenac-Na 90.77±21.5 127.95±32.7 77.52±23.9
+indomethacin 93.49±12.9 77.98±16.4a 52.76±34.2b
+meloxicam 61.82±26.1b 59.94±17.5b 71.37±19.0a
+naproxen 101.81±29.3 104.01±12.4 96.47±68.1
+dexamethasone 19.87±17.2c 6.71±7.4c 15.19±18.7c
Experiments were performed between culture days 6 and 8 in the presence of the serum substitute CR-ITS+Y.
Drugs were given to chondrocytes to a final concentration of 10 M. MMPs in media samples were activated with
APMA and analysed for enzymatic activities against PG monomers. MMP-3 mRNA and protein expression was
determined by RT-PCR-ELISA and immunoprecipitation, respectively. Values are expressed in mean±S.D.
(N=4–6). Data were analysed using Student’s one-tailed paired t-test. Statistical significance different from
control values (IL-1+vehicle=100%): a0.01<P≤0.05, b0.001<P≤0.01, cP≤0.001.
412 T. Sadowski and J. Steinmeyer: Effects of non-steroidal antiinflammatory drugsprotein and expression of GAPDH, whereas treatment of
chondrocytes with dexamethasone resulted in reduced
levels of protein synthesis with dose-dependent inhibition
ranging from 40% to 13% (data not shown).Table IV
TIMP activity and biosynthesis of TIMP-1 after treatment of chondrocytes with 0.5 ng/ml IL-1 and dexamethasone
or NSAIDs for 48 h
Activity Protein
synthesis
mRNA
expression
Dexamethasone
50 M 39.01±31.0b 32.64±30.9b 60.62±15.24c
10 M 60.93±30.3a 25.19±11.2c 55.20±26.5b
1 M 42.86±33.4a 34.55±17.7c 68.46±19.0b
0.1 M 39.46±19.1c 30.63±20.7c 72.01±21.9a
Meloxicam
50 M 77.90±15.4a 108.39±42.4 81.53±24.9
10 M 80.86±21.9a 131.63±45.8 96.31±20.6
5 M 82.58±68.4 125.34±55.3 84.26±42.2
1 M 83.33±45.4 112.60±23.4 97.09±33.7
ASA 104.14±17.3 72.12±36.4 78.92±13.3b
Diclofenac-Na 113.65±30.1 101.33±24.3 88.74±24.8
Indomethacin 127.32±33.8 89.15±24.1 99.85±25.8
Naproxen 92.45±29.3 139.76±92.0 94.02±32.4
Experiments were performed between culture days 6 and 8 in the presence of the serum substitute CR-ITS+Y.
Media and solubilized alginate samples were harvested and analysed for TIMP acitivity and TIMP-1 protein. For
determination of the mRNA expression, total RNA was isolated and transcript levels were quantitated by
RT-PCR-ELISA. All analyses were performed as described under Materials and methods. NSAIDs were tested at
a concentration of 10 M. Values are mean±S.D. (N=4–6). Statistical significance different from control values
(IL-1+vehicle=100%): a0.01<P≤0.05, b0.001<P≤0.01, cP≤0.001.Table III(b)
Proteoglycanolytic activity and biosynthesis of MMP-3 after treatment of chondrocytes with 0.5 ng/ml IL-1 and
various concentrations of NSAIDs and dexamethasone for 48 h
Condition Enzyme
activity
MMP-3
protein synthesis
MMP-3
mRNA expression
Dexamethasone
50 M 17.48±19.5c 16.08±19.2c 26.28±31.9b
1 M 8.76±17.8c 22.67±27.4c 25.64±16.6c
0.1 M 14.06±19.6c 14.16±16.2c 14.58±25.0b
Indomethacin
50 M 55.45±20.8b 56.81±20.0b 53.92±10.2c
5 M 77.49±34.2 84.86±31.9 116.72±7.3
1 M 73.77±28.1 86.13±27.4 70.43±49.4
Meloxicam
50 M 60.71±29.0a 77.74±16.2a 31.93±14.4b
5 M 83.65±32.1b 115.31±41.6 n.d.
1 M 86.12±22.7 97.00±52.9 76.00±37.9
Experiments were performed between culture days 6 and 8 in the presence of the serum substitute CR-ITS+Y.
Enzyme activities were determined in media samples. Total RNA was isolated and analysed by RT-PCR-ELISA.
Protein synthesis of MMP-3 was quantitated by immunoprecipitation. All analyses were performed as described
under Materials and methods. Values are mean±S.D. (N=4–6). Statistical significance different from control values
(IL-1+vehicle=100%): b0.001<P≤0.01, cP≤0.001.
n.d.: not determined.action on glycosaminoglycan synthesis, NSAIDs could be
divided into types with stimulatory, inhibitory and neutral
properties35,36. Further identification of differences be-
tween currently used antirheumatic drugs could thus help
to choose an appropriate pharmacotherapy of OA and RA.
The goal of our study was therefore to compare the effects
of various NSAIDs and dexamethasone on the regulation of
catabolic activity by articular chondrocytes.
Our data indicate that all tested NSAIDs significantly
reduced the IL-1 stimulated collagenolytic acitivity. In the
case of indomethacin, meloxicam and naproxen this was
achieved by down-regulating the gene expression of
MMP-1, whereas reduction of enzyme activity by ASA and
diclofenac-Na appears to be not mediated via reducedDiscussion
Glucocorticoids, and especially NSAIDs, belong to the
most commonly used drugs for OA and RA treatment. The
therapeutic efficacy of NSAIDs in modulating pain and
inflammation is generally believed to be the result of
prostaglandin inhibition. However, many NSAIDs have
been reported also to influence cartilage metabolism to
varying degrees. For instance, with regard to their in vitro
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